Conjugate of cytotoxic drug and prodrug form of said conjugate
Patent Information
- Application Number
- CA3095146
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-02
- Filing Date
- 2019-04-02
- Publication Date
- 2026-10-13
- Estimated Expiration
- 2039-04-02
AI Technical Summary
Current cancer treatments using cytotoxic drugs like dolastatin and auristatin derivatives suffer from lack of selectivity, leading to severe side effects due to non-specific targeting of healthy tissues, necessitating the development of protein-drug conjugates that require efficient drug release mechanisms within cancer cells while maintaining linker stability in circulation.
A conjugate with a self-immolative moiety between the cytotoxic drug and the linker, specifically a 13-glucuronidase-responsive albumin-binding conjugate, where the self-immolative moiety increases stability and enables enzymatic cleavage of the cytotoxic drug, particularly utilizing (R)-4-(1-hydroxybut-3-yn-1-y1)-2-nitro-phenol and its derivatives, to enhance targeted drug delivery.
The conjugate achieves higher enzymatic cleavage kinetics and stability, allowing for targeted release of the cytotoxic drug within cancer cells, reducing side effects and improving treatment efficacy by enhancing selectivity and bioavailability.
Abstract
Description
<DP=1>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²1²Conjugate of cytotoxic drug and prodrug form of said conjugate²FIELD OF THE INVENTION²The present invention relates to a specific conjugate of cytotoxic drugs and ²prodrug forms of²said conjugate, for use in treating cancer and inflammatory diseases.²TECHNICAL BACKGROUND²Cancer and inflammatory diseases are among the most frequent illnesses ²nowadays. In ²particular, cancer is one of the most important cause of death in ²industrialized countries, and ²the number of people diagnosed with cancer continues to grow at the current ²time.²Several treatment modes have been developed so far, however chemotherapy ²remains the only ²one that can be used against circulating tumors, such as lymphomas and ²leukemias, and² metastases.²In chemotherapy, one strategy lies in inhibiting polymerization of tubulin and ²thus preventing ²cell division (antimitotics). This can be achieved by using compounds of the ²dolastatin family, ²in particular, natural dolastatin 10, which can be isolated from the Indian ²Ocean sea hare ²Dolabella auricularia and consists of four amino-acids, three of which being ²specific thereto.²Synthetic derivatives of dolastatin 10 such as auristatin PE, auristatin E and ²monomethyl²auristatin E (MMAE) also exist and have proven to be efficient inhibitors. The ²major flaw of ²such compounds lies in the lack of selectivity towards cancer cells, resulting ²in the destruction ²of healthy tissues and therefore intense side effects, such as hair loss or ²nausea. The ²development of protein-drug conjugates of such active agents has appeared as ²an elegant and²efficient strategy to overcome the lack of selectivity.²Protein-drug conjugates are by far the fastest growing class of highly potent ²active ²pharmaceutical ingredients. Protein-drug conjugate constructs generally ²involve a protein, such ²as an antibody, covalently attached to one end of a linker group, on the other ²end of which is a ²cytotoxin, i.e. a highly potent cell killing toxin. The protein component of ²the biomolecule²provides target specificity. Once the conjugate enters the cell, the toxin is ²released, for instance²by action of cellular enzymes. Most protein-drug conjugates are indeed ²directed to cancer ²treatment. Besides the marketed trastuzumab emtansine (referred to as T-DM1 or ²Kadcyla ) ²and the brentuximab vedotin (Adcetris8), a number of protein-drug conjugates ²are currently ²undergoing clinical trials for a variety of cancer indications.²<DP=2>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²2²One of the main prerequisites for the activity of such conjugates is the ²efficient release of the ²cytotoxic drug upon internalization by cancer cells, while the linker between ²the protein and ²drug should be stable in blood circulation before the conjugate reaches its ²biological target.²In this respect, a real breakthrough was achieved by the introduction of ²enzyme-cleavable² linkers into the conjugate construct.²WO 2015 / 118497 thus describes the 13-glucuronidase-responsive albumin-binding ²conjugate of ²formula (I),²o²o²)==?²Ay * V NC3INI²H²0 N=N / ²0²OH². NO2²0²HOHC)²OH² (I),²wherein A is typically MMAE. Its maleimide end moiety is intended to provide ²selective ²coupling with a circulating albumin after intravenous administration. A ²glucuronide moiety, ²which is glucuronidase sensitive, is also present in the molecule and is ²linked to a self-reactive ²arm. Since albumin accumulates in tumors and 13-glucuronidase is present in ²the tumor²environment, the compound reaches the tumor site where the enzyme catalyzes ²the cleavage of²the glycoside bond and then triggers the release of the drug (MMAE). The ²conjugate exists as ²a 1:1 mixture of two isomers, whose varying stereogenic center is on the self-²reactive arm ²(labelled with a star on formula (I)).² SUMMARY OF THE INVENTION²The inventors demonstrated that the two isomers of the above conjugate, which ²could not be ²separated by means of conventional techniques, could be obtained from HPLC ²enantiomeric ²separation of an early intermediate. The two isolated isomers were proven ²stable, especially in²human plasma, but the isomer whose varying stereogenic center has an R ²configuration ²displayed a higher enzymatic cleavage kinetics than the other one. This higher ²kinetics observed²<DP=3>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²3²with one isomer is all the more so unexpected that the stereogenic center is ²not part of the ²pharmacophore recognized by the enzyme. This unexpected feature may ²particularly be ²beneficial for patients having a lower enzyme expression.²The inventors have also demonstrated that the insertion of a self-immolative ²moiety into the²structure, more specifically between the cytotoxic drug and the remainder of ²the conjugate, can²increase the stability of the conjugate, while preserving its ability to be ²cleaved (i.e. to release ²the cytotoxic drug).²Said isomer, which the present invention relates thereto, is a conjugate ²represented by formula² (I):²0²0²A 4=G ny ²0²........²0 N=N ²0²0 H²= NO2²0²0 H²(I),²wherein A represents a radical deriving from a cytotoxic drug,² G is a self-immolative moiety, and²m is 0 or 1,²and pharmaceutically acceptable salts thereof²The invention further provides a process for preparing a conjugate as defined ²above, comprising²the steps of:²a) preparing ² rac-4-( 1 -hydroxybut-3 -yn- 1 -y1)-2 -nitro-phenol from 4-hydroxy-3 -²nitrob enzaldehyde ;²b) separating and isolating (R)-4-(1-hydroxybut-3-yn- 1-y1)-2-nitro-phenol, ²preferably by chiral ²high-performance liquid chromatography;²c) reacting (R)-4-(1-hydroxybut-3-yn- 1-y1)-2-nitro-phenol with a glucuronic ²acid derivative,²such as methyl acetobromo-a-D-glucuronate, under basic conditions;²d) reacting the compound obtained in step (c) with 4-nitrophenyl ²chloroformate;²<DP=4>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²4²e) coupling the compound obtained in step (d) with a cytotoxic drug or with an ²A-G-H moiety, ²in which A represents a radical deriving from a cytotoxic drug and G ²represents a self-²immolative moiety;²f) deprotecting the glucuronide moiety of the compound obtained in step (e), ²preferably under² basic conditions; and²g) coupling the compound obtained in step (f) with an azide of formula N3-(CH2-²CH2-0)io-²(CH2)2-NH-(C0)-(CH2)5-X, wherein X is a maleimide group.²The invention also relates to a prodrug comprising at least one molecule of ²the conjugate as²defined above, said molecule of the conjugate being linked via a covalent bond ²to a protein²molecule, preferably albumin, or a fragment or a derivative thereof²It is further directed to a pharmaceutical composition comprising at least an ²effective amount ²of at least one conjugate as defined above or at least one prodrug as defined ²above, and a²pharmaceutically acceptable carrier.²This invention still further relates independently to a conjugate as defined ²above, a prodrug as²defined above or a pharmaceutical composition as defined above for use in ²treating a cancer²and / or an inflammatory disease.² BRIEF DESCRIPTION OF THE DRAWINGS²Figure 1 shows the molecular structure of compound Rla from X-ray ²crystallography. ²Displacement ellipsoids are drawn at the 50% probability level.²Figure 2 shows the kinetics of13-glucuronidase-induced release of MMAE in ²plasma solutions²of compounds R5 and S5.²Figure 3 shows the kinetics of13-glucuronidase-induced release of MMAF in ²plasma solutions²of compounds R6 and S6.²Figure 4 shows the kinetics of 13-glucuronidase-induced release of SN-38 in ²plasma solutions² of compounds R7 and S7.²Figure 5 shows the kinetics of 13-glucuronidase-induced release of Doxorubicin ²in plasma²solutions of compounds R8 and S8.²Figure 6 shows the stability of compounds R5 and S5 in PBS at pH 7.4.²Figure 7 shows the plasma-binding kinetics of compounds R5 and S5.²<DP=5>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226² Figure 8 shows the plasma stability of albumin-bound R5 and S5.²Figure 9 shows the HPLC profile of the 1:1 mixture of R5 and S5.²Figure 10 shows the HPLC profile of the 1:1 mixture of R4 and S4.² 5 DETAILED DESCRIPTION OF THE INVENTION²Conjugates ²The invention relates to a conjugate having the following formula (I):²o²0²A 4G*3 H²0 N =N ²0²0 H²I. NO2²0²H OHC)²0 H² (I),²wherein A represents a radical deriving from a cytotoxic drug,²G is a self-immolative moiety, and²m is 0 or 1,²and pharmaceutically acceptable salts thereof²In the context of the invention, a "pharmaceutically acceptable salt" refers ²to a salt of a²conjugate or of a prodrug or of a drug according to the invention, and of an ²alkali metal, of an²alkaline-earth metal, or of ammonium, comprising the salts obtained with ²organic ammonium²bases, or salts of a conjugate, or of a prodrug or of a drug according to the ²invention, and of an² organic or inorganic acid.²Salts which are more particularly suitable for the invention may be sodium, ²potassium, calcium, ²magnesium salts, quaternary ammonium salts such as tetramethylammonium or ²tetraethylammonium, and addition salts with ammonia and pharmaceutically ²acceptable ²organic amines, such as methylamine, dimethylamine, trimethylamine, ²ethylamine,²triethylamine, ethanolamine or tris(2-hydroxyethyl)amine.²<DP=6>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²6²Salts of a conjugate, or of a prodrug or of a drug according to the invention, ²and of an inorganic ²acid that are suitable for the invention may be obtained with hydrochloric ²acid, hydrobromic ²acid, sulfuric acid, nitric acid or phosphoric acid.²Salts of a conjugate, or of a prodrug or of a drug according to the invention, ²and of an organic²acid that are suitable for the invention may be obtained with carboxylic acids ²and sulfonic acids, ²such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic ²acid, succinic acid, ²malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, ²methanesulfonic acid, ²benzenesulfonic acid or p-toluenesulfonic acid.²According to the invention, a "self-immolative moiety" denotes a divalent ²chemical group ²which connects the radical deriving from a cytotoxic drug with the remainder ²of the conjugate, ²and which becomes labile upon activation (e.g. enzymatic cleavage of ²glucuronide residue), ²leading to a release of the free moieties, in particular the cytotoxic drug. ²Self immolative ²moieties are well-known to the skilled artisan (Polym. Chem. 2011, 2, 773-²790).² In one embodiment, m is 0.²In another embodiment, m is 1 and G is represented by a formula selected from:²\CN)\²0²0²,and² In a preferred embodiment, G is represented by the following formula:²el NA'²=²According to the invention, a "radical deriving from a cytotoxic drug" denotes ²a moiety ²consisting of a cytotoxic drug deprived of one or more atoms of one of its ²functional groups ²(for instance, a H atom) which has reacted with the remainder of the ²conjugate.²<DP=7>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²7²The drug according to the invention is a cytotoxic drug. As used herein, the ²term "cytotoxic ²drug" refers to a molecule that when entering in contact with a cell, ²optionally upon ²internalization into the cell, alters a cell function (e.g. cell growth and / or ²proliferation and / or²differentiation and / or metabolism such as protein and / or DNA synthesis) in a ²detrimental way²or leads to cell death. As used herein, the term "cytotoxic drug" encompasses ²toxins, in ²particular cytotoxins. In principle, a cytotoxic drug is defined as a LO1 ATC ²molecule ²("Anatomical Therapeutic Chemical Classification System" where LO1 is a ²subgroup defining ²antineoplastic and immunomodulating agents defined by WHO Collaborating Centre ²for Drug² Statistics Methodology).²The cytotoxic drug according to the invention may be selected from dolastatins ²such as ²dolastatin 10, dolastatin 15, auristatin E, auristatin EB (AEB), auristatin ²EFP (AEFP), ²monomethyl auristatin F (MMAF), monomethylauristatin-D (MMAD), monomethyl ²auristatin² E (MMAE), 5-benzoylvaleric acid-AE ester (AEVB) or derivatives thereof.²Preferred dolastatins are MMAF, MMAD, MMAE, or derivatives thereof.²More preferred dolastatins are MMAE, MMAF, or derivatives thereof.²In a particular embodiment, the cytotoxic drug according to the invention is ²an anthracycline²such as doxorubicin, idarubicin, epirubicin, daunorubicin, or valrubicin, ²preferably² doxorubicin.²In another particular embodiment, the cytotoxic drug according to the ²invention is a drug of the ²camptothecin family (also referred herein to as "camptothecin analog"), such ²as camptothecin, ²SN-38, topotecan, irinotecan, exatecan, silatecan, cositecan, lurtotecan, ²gimatecan, belotecan, ²or rubitecan, preferably SN-38, exatecan, belotecanõ and more preferably SN-²38.²In a preferred embodiment, the cytotoxic drug is selected from doxorubicin, SN-²38, MMAE,²MMAF, MMAD, and derivatives thereof.²Dolastatins are a family of compounds having a structure of at least 4 amino-²acids, preferably ²4 amino-acids, at least 3 of which being specific thereto, since different ²from the 20 amino-²acids commonly found naturally. According to the invention, a derivative of ²dolastatin has a²chemical structure very related to at least one compound of the dolastatin ²family and displays ²similar antimitotic properties. Structural differences between said derivative ²and a compound ²of the dolastatin family may lie in a substitution on at least one side chain ²of at least one amino-²acid by any suitable substituent commonly found. For example, said substituent ²may be:²<DP=8>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²8²- an alkyl group, i.e. a linear or branched saturated hydrocarbon chain, ²such as a methyl, ethyl,²propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, ²nonyl or decyl group;²- a heteroalkyl group, i.e. a linear or branched hydrocarbon chain ²interrupted by one or more ²heteroatom(s), mainly 0, N and S, such a methoxy or ethoxy group;²- an aryl group, i.e. an aromatic carbocyclic group, such as a phenyl or ²naphthyl group, which²may optionally be substituted with up to four groups including, but not ²limited to: -COOH, - ²SO3H, -OCH3, -F, -Cl, -Br, -I, -OH, -NH2, -NO2, -CN;²- a heteroaryl group, i.e. an aromatic group which contains one or more ²heteratoms, such as a ²pyridyl, oxazolyl, furanyl or thiazolyl group; or² - a halogen atom, such as -F, -Cl, -Br, -I.²The structural difference may also consist of a modification of a dolastatin ²such as dolastatin ²10, dolastatin 15, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), ²monomethyl ²auristatin F (MMAF), monomethylauristatin-D (MMAD), monomethyl auristatin E ²(MMAE), ²or 5-benzoylvaleric acid-AE ester (AEVB), for example at the level of its ²tertiary amine in the²N-terminal position, so as to render this function compatible with the ²establishment of a²covalent bond with the linker arm under consideration.²The skilled artisan is able to select suitable modifications, in particular ²suitable substituents, for ²these purposes.²According to another embodiment, the drug may be selected from mytansins such ²as DM1 and²DM4, anthracyclines such as doxorubicin, nemorubicin and PNU-159682, ²calicheamicins, ²duocarymycins such as CC-1065 and duocarmycin A, pyrrolobenzodiazepines, ²pyrrolobenzodiazepine dimers, indolino-benzodiazepines, indolino-²benzodiazepine dimers, a-²amanitins, eribulin, acalabrutinib, bleomycin, beritinib, cladribine, ²clofarabine, cobimetinib, ²copanlisib, crizotinib, cytarabine, dabrafenib, dactinomycin, daunorubicin, ²decitabine,²epirubicin, ibrutinib, idarubicin, lapatinib, lenalidomide, mitomycin C, ²mitoxantrone, ²nelarabine, niraparib, paclitaxel, panobinostat, pomalidomide, prednisone, ²ribociclib, ²palbocicilb, rolapitant, rucaparib, sonidegib, tamoxifen, temsirolimus, ²topotecan, trabectedin, ²valrubicin, vinblastine, vincristine, and pharmaceutically acceptable salts ²thereof.²lei NA,²H² In a particular embodiment, the cytotoxic drug is SN-38, m is 1 and G is .²<DP=9>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²9²In a another particular embodiment, the cytotoxic drug is a dolastatin or an ²anthracycline, and ²m is O.²Process ²The term "solvent" refers to organic solvent, inorganic solvent such as water, ²or a mixture ²thereof. Examples of organic solvents include, but are not limited to, ²aliphatic hydrocarbons ²such as pentane or hexane, alicyclic hydrocarbons such as cyclohexane, ²aromatic hydrocarbons ²such as benzene, styrene, toluene, ortho-xylene, meta-xylene or para-xylene, ²halogenated²hydrocarbons such as dichloromethane, chloroform or chlorobenzene, nitrogen-²based solvents ²such as pyridine, acetonitrile or triethylamine, oxygen-based solvents, in ²particular ketones ²such as acetone, ethers such as diethyl ether, tert-butyl methyl ether (TBME), ²cyclopentyl ²methyl ether (CPME), tetrahydrofuran (THF) or methyl tetrahydrofuran (Me-THF), ²and ²alcohols such as methanol or ethanol, esters such as n-butyl acetate, or ²amides such as² dimethylformamide (DMF), and mixtures thereof²"Acid conditions" refers to conditions wherein one or more acids are used. ²Examples of acid ²include, but are not limited to, hydrochloric acid, hydrobromic acid, ²hydriodic acid, ²hydrofluoric acid, nitric acid, sulfuric acid, hexafluorophosphoric acid, ²tetrafluoroboric acid,²trifluoroacetic acid, acetic acid, sulfonic acid such as methanesulfonic acid, ²mono- or ²polycarboxylic acid, or mixtures thereof, preferably hydrochloric acid.²"Basic conditions" refers to conditions wherein one or more bases are used. ²Examples of base ²include, but are not limited to, lithium hydroxide or sodium hydroxide, ²carbonates such as²potassium carbonate, sodium carbonate or sodium hydrogenocarbonate, alkoxides ²such as ²sodium methoxide, amines such as triethylamine, and nitrogen-based cyclic ²bases, such as ²imidazole, N-methylimidazole, pyridine or dimethyl-amino-pyridine (DMAP), ²preferably ²lithium hydroxide.²The conjugate according the invention may be prepared from commercial 4-²hydroxy-3-²nitrobenzaldehyde, through a multi-step synthesis, including a step of ²enantiomeric separation ²of the rac-4-( 1 -hydroxybut-3 -yn- 1 -y1)-2 -nitro-phenol intermediate by ²chiral high-performance ²liquid chromatography (HPLC).²<DP=10>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²Conditions (temperature, concentration, solvents, reactants, equivalents of ²the reactants) ²described below for each step may be adjusted by the skilled artisan using ²his / her general ²background in organic synthesis. Each intermediate or product obtained at the ²end of a step ²may be isolated and optionally purified, or alternatively, several steps may ²be carried out one-²5 pot without isolating said intermediate or product. The order of the ²process steps described²below may be modified.²Step (a)²In one embodiment, rac-4-(1-Hydroxybut-3-yn- 1-y1)-2-nitro-phenol may be ²prepared in one²10 step from 4-hydroxy-3-nitrobenzaldehyde. The reaction consists in ²introducing a propargyl²group by addition of the latter on the aldehyde function of 4-hydroxy-3-²nitrobenzaldehyde. ²Typically, said reaction may be performed by reacting 4-hydroxy-3-²nitrobenzaldehyde with a ²nucleophilic propargyl group, i.e. any anionic or organometallic form of the ²propargyl group, ²which is able to add on an electrophilic site. Said reaction may be assisted ²with a catalyst, such²as HgC12. Said nucleophilic propargyl group may be formed in situ or ²beforehand prepared in²a separate vessel, from any propargyl source such as propargyl bromide. In a ²preferred ²embodiment, the reaction is performed with 4-hydroxy-3-nitrobenzaldehyde and ²propargyl ²bromide in the presence of aluminum metal and HgC12.² Step (b)²Then, the two enantiomers of rac-4-(1-Hydroxybut-3-yn-1-y1)-2-nitro-phenol may ²be separated ²by means of a technique such as chiral HPLC, formation and separation of ²diastereoisomer ²salts, crystallization, catalytic resolution or enzymatic resolution, or ²combinations thereof. ²Preferably, the two enantiomers are separated by chiral HPLC. Chiral HPLC is a²chromatography technique which stationary phase is chiral. The chiral ²stationary phase may be²an amylose-based, cyclodextrin-based or cellulose-based phase. Preferably, the ²chiral ²stationary phase is an amylose-based phase.²This step of enantiomeric separation allows to isolate (R)-4-(1-hydroxybut-3-²yn- 1-y1)-2-nitro-²phenol. The enantiomeric purity of (R)-4-(1-hydroxybut-3-yn-1-y1)-2-nitro-²phenol after the²separation step is advantageously more than 90%, preferably more than 95%. ²Enantiomeric²purity may be measured by means of analytical chiral HPLC.²<DP=11>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²11²Step (c)²For the purpose of introducing the glucuronide moiety, (R)-4-(1-hydroxybut-3-²yn- 1-y1)-2-²nitro-phenol may be reacted with a glucuronic acid derivative, under ²conditions allowing the ²selective 0-glucuronidation of the phenol group. Preferably, said glucuronic ²acid derivative is²a fully-protected glucuronic acid, typically an acetylated glucuronate, and is ²functionalized so²that it can react with the phenol group. Said glucuronic acid derivative is ²preferably an alkyl ²acetobromo-a-D-glucuronate, more preferably methyl acetobromo-a-D-glucuronate. ²In a ²preferred embodiment, the 0-glucuronidation of the phenol group is carried out ²under basic ²conditions. For example, the reaction may be carried out in the presence of ²Ag2CO3 and² .. HMTTA (1 , 1 ,4,7, 1 0, 1 0-hex amethyltriethyl enetetramine).²Step (d)²The 0-glucuronidation product obtained in step (c) may be converted for the ²purpose of²coupling step (e). To this end, the secondary alcohol function of said product ²may be reacted²with a chloroformate, preferably 4-nitrophenyl chloroformate, resulting in the ²formation of a²carbonate. The reaction may be catalyzed by a nucleophile, which may also act ²as a base, such ²as pyridine.²Steps (e), 0 and (g)²In step (e), the compound obtained in step (d) is then linked to a cytotoxic ²drug as defined above²(such as MMAE), or with an A-G-H moiety, in which A represents a radical ²deriving from a ²cytotoxic drug and G represents a self-immolative moiety. In a first ²embodiment, where the ²cytotoxic drug is directly linked to the compound obtained in step (d), the ²amine group (or ²hydroxy group) of said cytotoxic drug reacts with the carbonate of the ²compound obtained in²step (d) to generate an amide group. An activating agent may be used, such as ²HOAt, HOBt,²HOCt. Preferably, said activating agent is HOBt.²Implementation of steps (f) and (g) as described below, subsequently to such a ²first ²embodiment, leads to a conjugate of formula (I) as defined above, wherein m is ²0.²In a second embodiment, where the cytotoxic drug is linked to the compound ²obtained in step²(d) through a self-immolative moiety, the compound obtained in step (d) is ²reacted with an A-²G-H moiety, in which A represents a radical deriving from a cytotoxic drug and ²G represents a ²self-immolative moiety.²<DP=12>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²12²A-G-H connects to the compound obtained in step (d) through a functional ²group, which is ²advantageously -NH2 or -NH-.²Examples of A-G-H moieties include, but are not limited to:² A NH²41)²A NH²I²A yNNH A H N 0²A N NH H2 0 2 , / N , and²5 5 .²Said A-G-H moiety can typically be prepared by reacting a cytotoxic drug with ²a compound of ²formula X-G-H, wherein X represents a leaving group, such as a sulfonate (e.g.²methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, ²nitrobenzenesulfonate), or a ²halogen (e.g. a chlorine, a bromine, a iodine). Preferably, X is bromine. The ²cytotoxic drug ²reacts typically with X-G-H, through its (or one of its) amine or hydroxy ²group, to form A-G-²H as defined above. In a particular embodiment, X-G-H is in a protected form ²when reacting ²with the cytotoxic drug. A "protected form" refers to a form wherein one or ²more reactive²functional groups of the compound exist in an unreactive form, such as a NH2 ²group protected ²in the form of a N3 group. After reacting X-G-H with the cytotoxic drug, A-G-H ²is obtained ²and may be in a "protected form" as well. Said A-G-H may be "deprotected" in ²order to free ²the reactive functional group(s) (for instance, converting a N3 group into a ²NH2 group).²Implementation of steps (f) and (g) as described below, subsequently to such a ²second ²embodiment, leads to a conjugate of formula (I) as defined above, wherein m is ²1.²In one embodiment, deprotection of acetyl and ester functions on the ²glucuronide moiety into ²hydroxy and carboxylic acid functions, respectively, is then carried out in ²step (f). Said step (f)²of deprotecting the glucuronide moiety of the compound obtained in step (e) is ²preferably ²carried out under basic conditions, and more preferably under basic conditions ²at a low ²temperature. Alternatively, said step (f) can be carried out under acid ²conditions, and in any ²organic solvent, such as acetonitrile. The alkyne function of the compound ²obtained in step (f) ²is then coupled with an azide of formula N3-(CH2-CH2-0)1o4CH2)2-NH-CO-(CH2)5-²X, wherein²<DP=13>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²13²X is a maleimide group, under well-known click-chemistry conditions, allowing ²the selective ²formation of the 1,4-disubstituted triazole regioisomer, and thus the ²formation of a conjugate ²of the invention.²The azide of formula N3-(CH2-CH2-0)10-(CH2)2-NH-00-(CH2)5-X, wherein X is a ²maleimide²group, may be typically obtained by reacting N3-(CH2-CH2-0)io-(CH2)2-NH2 with ²2,5-²dioxopyrro lidin-1 -yl 6-(2,5 -dioxo-2 ,5 -dihydro-1H-pyrrol-1 -yl)hexano ate ².²In another embodiment, step (f) consists in coupling the compound obtained in ²step (e) with the²azide of formula N3-(CH2-CH2-0)io-(CH2)2-NH2 under click-chemistry conditions, ²allowing²the selective formation of the 1,4-disubstituted triazole regioisomer. In step ²(g), the -NH2 group ²is converted to an alkylamide substituted with a maleimide group at the end of ²the alkyl chain, ²typically by reacting the compound obtained in step (f) with 2,5-²dioxopyrrolidin- 1 -yl 6-(2,5-²dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate. A final deprotection of the ²glucuronide moiety²of the compound obtained in step (g) is then carried out. This deprotection is ²preferably carried²out under basic conditions, and more preferably under basic conditions at a ²low temperature.²The process according to the invention provides access to a conjugate existing ²as a single²isomer, whose purity is advantageously more than 90%, preferably more than ²95%.² Prodrug²The conjugate according to the invention contains a maleimide group, which is ²very reactive ²towards nucleophilic groups, and more specifically towards a thiol group (-²SH). Such groups²typically add on the maleimide moiety through a Michael addition. The ²maleimide group is²therefore a reactive group of choice for coupling a conjugate of the invention ²with a ²macromolecule. In the context of the invention, the macromolecule is ²preferably an endogenous ²molecule.²According to the invention, a prodrug refers to at least one conjugate ²covalently linked to a²macromolecule, more specifically a protein. Said prodrug is capable of ²transporting, in an ²inactivated form, a cytotoxic drug in an organism, and of releasing said drug ²into an organ, a ²tissue or cells, which is (are) specifically targeted, under the action of a ²13-glucuronidase. The²<DP=14>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²14²prodrug may be formed in vivo or in vitro by reacting with a macromolecule, ²more specifically ²a protein.²In particular, the protein is selected from those which bind specifically a ²molecule present at²the membrane of a cancer cell, preferably a molecule selected from the group ²consisting of²proteins, glycoproteins, glycolipids, carbohydrates, or a combination thereof, ²even more ²preferably the protein binds specifically a protein present at the membrane of ²a cancer cell. The ²membrane molecule to which the protein is capable to bind to is a molecule ²mainly or ²exclusively present at the membrane of a cancer cell. In a particular ²embodiment, the membrane²molecule recognized by the protein is a protein overexpressed at the membrane ²of a cancer cell.²In a preferred embodiment, the protein may be selected from the group ²consisting of antibodies ²and albumins.²As used herein, the terms "antibody" refers to immunoglobulin molecules and ²immunologically²active portions of immunoglobulin molecules, i.e., molecules that contain an ²antigen-binding²site that immunospecifically binds an antigen. As such, the term antibody ²encompasses not only ²whole antibody molecules, but also antigen-binding antibody fragments as well ²as variants ²(including derivatives) of antibodies and antibody fragments. In particular, ²the antibody ²according to the invention may correspond to a monoclonal antibody (e.g. a ²chimeric,²humanized or human antibody), or a fragment of monoclonal antibody. The term ²antibody²refers to classical antibodies as well as to heavy-chain antibodies and ²fragments and derivatives ²thereof such as (VHH)2 fragments and single domain antibodies.²Antibody fragments that recognize specific epitopes can be generated by known ²techniques. ²The antibody fragments are antigen binding portions of an antibody, such as ²F(ab')2, Fab, Fv,²scFv and the like. Other antibody fragments include, but are not limited to: ²the F(ab')2²fragments which can be produced by pepsin digestion of the antibody molecule ²and the Fab' ²fragments, which can be generated by reducing disulfide bridges of the F(ab')2 ²fragments. ²Alternatively, Fab' expression libraries can be constructed (Huse et al., ²1989, Science, ²246:1274-1281) to allow rapid and easy identification of monoclonal Fab' ²fragments with the² desired specificity.²Antibodies according to the invention may be produced by any technique known ²in the art, such ²as, without limitation, any chemical, biological, genetic or enzymatic ²technique, either alone or ²in combination. The antibodies of the invention can be obtained by producing ²and culturing²<DP=15>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²hybridomas. See also WO 2015 / 063331 for the production of synthetic single ²domain ²antibodies.²The antibody according to the invention may be a monomeric antibody or a ²multimeric antibody ²and it may comprise at least a variable domain, in particular when the ²antibody is multimeric.²5 Preferably, the antibody according to the invention is IgG, preferably ²subtypes IgG1 or IgG4,²for example trastuzumab or rituximab.²In a most preferred embodiment of this invention, the protein is an albumin ²molecule, which ²has free thiol functions. An endogenous or exogenous albumin, and in ²particular a human serum²10 albumin, a recombinant albumin or a fragment of an albumin, may be ²envisaged.²Endogenous albumin is known to accumulate via the "EPR" ("Enhanced ²Permeability and ²Retention") effect in the microenvironment of solid tumors, therefore the in ²situ coupling of a ²conjugate according to the invention with an endogenous albumin molecule makes ²it possible²15 to target the coupled entity thus formed, also called prodrug, into the ²tumor microenvironment²and thus to overcome the lack of selectivity of the free forms of some ²cytotoxic drug derivatives, ²such as dolastatins. It should be noted that such an "EPR" effect applies to ²the ²microenvironment of inflamed tissues.²A prodrug may thus be obtained via the selective formation, in vivo, of a ²covalent bond between²the conjugate, through its reactive maleimide group, and a free and ²complementary reactive ²function, typically a thiol function, of a protein, preferably an endogenous ²albumin molecule, ²more preferably a human serum albumin, or a derivative thereof. Said prodrug ²may comprise ²at least one molecule of the conjugate according to the invention, covalently ²linked to a protein² molecule or a fragment or a derivative of the molecule.²In the case of albumin, said covalent bond may be established with the thiol ²function of the²cysteine in position 34 of the albumin.²In a particular embodiment, the prodrug of the invention may be prepared prior ²to its²administration. The prodrug of the invention may be formed in vitro through ²the formation of²a covalent bond between at least one conjugate of the invention and a free and ²complementary ²function, typically a thiol function, of a protein such as an albumin ²molecule, a recombinant ²albumin molecule or a fragment or a derivative thereof Said covalent bond may ²be established ²with the thiol function of the cysteine in position 34 of the albumin.²<DP=16>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²16²In the context of the invention, "fragment of an albumin molecule" denotes a ²fragment of an ²albumin molecule having a size sufficient to guarantee satisfactory ²bioavailability, permeability ²with respect to tumor tissues and impermeability with respect to the ²endothelial barrier of²healthy tissues, of the prodrug thus generated. In a particular embodiment, ²the fragment of an²albumin molecule contains the cysteine corresponding to the cysteine 34 of the ²endogenous ²albumin sequence.²The prodrug according to the invention may be represented by formula (II): ² Prt²0²0 n².......1:)N)N² / H²0 N=N 0²0 H²HO ². NO2²0²0 H²(II),²wherein A, G, and m are as defined above,² Prt represents a radical deriving from a protein,²n is comprised between 0.1 and 16, preferably between 0.1 and 8,²and pharmaceutically acceptable salts thereof²In one particular embodiment, Prt represents a radical deriving from an ²antibody and n is the²mean number of conjugates attached to said antibody and is comprised between ²0.1 and 16,²preferably between 0.1 and 8.²In another particular embodiment, Prt represents a radical deriving from ²albumin and n is 1.²n may be measured by Mass Spectrometry (MS) and hydrophobic Interaction ²Chromatography²(HIC).²<DP=17>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²17²According to the invention, a "radical deriving from a protein" denotes a ²moiety consisting of ²a protein deprived of one or more atoms of one of its functional groups which ²has reacted with ²the remainder of the conjugate. More specifically, a "radical deriving from a ²protein" denotes²a protein comprising at least one cysteine moiety which has been deprived of ²the hydrogen atom²of its -SH group.²Pharmaceutical compositions ²The conjugates or prodrugs of this invention may be delivered in a ²pharmaceutical composition²comprising at least an effective amount of at least one conjugate of the ²invention or at least one ²prodrug of the invention, and a pharmaceutically acceptable carrier. The ²pharmaceutical ²composition may be in a solid or liquid state and may be in any of the ²pharmaceutical forms ²commonly used in human and / or veterinary medicine, for example in the form of ²simple or²sugar-coated tablets, of pills, of lozenges, of gel capsules, of drops, of ²granules, of injectable²preparations, of ointments, of creams or of gels. The pharmaceutical ²composition may be ²prepared according to the usual methods.²As used herein, the term "pharmaceutically acceptable carrier" refers to any ²ingredient except ²active ingredients (namely excipients) that is present in a pharmaceutical ²composition. Its²addition may be aimed at conferring a particular consistency or other physical ²or gustative²properties to the final product. An excipient or pharmaceutically acceptable ²carrier must be ²devoid of any interaction, in particular chemical, with the actives ²ingredients. Conventional ²excipients can be used according to techniques well known by those skilled in ²the art. As used ²herein, the term "effective amount" refers to a quantity of an active ²ingredient, which prevents,² removes or reduces the deleterious effects of the disease.²Uses²The conjugates of the invention or prodrugs of the invention may be used for ²treating cancer² and / or an inflammatory disease.²As used herein, the term "treatment", "treat" or "treating" refers to any act ²intended to ²ameliorate the health status of patients such as therapy, prevention, ²prophylaxis and retardation²<DP=18>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²18²of the disease. In certain embodiments, such term refers to the amelioration ²or eradication of a ²disease or symptoms associated with a disease. In other embodiments, this term ²refers to ²minimizing the spread or worsening of the disease resulting from the ²administration of one or ²more therapeutic agents to a subject with such a disease.²As used herein, the terms "subject", "individual" or "patient" are ²interchangeable and refer to²an animal, preferably to a mammal, even more preferably to a human. However, ²the term ²"subject" can also refer to non-human animals, in particular mammals. The ²subject according ²to the invention is an animal, preferably a mammal, even more preferably a ²human. The subject ²may be a non-human animal, in particular selected from mammals such as dogs, ²cats, horses,²cows, pigs, sheep and non-human primates, among others. Preferably, the ²subject is human,²preferably an adult, more preferably an adult of at least 40 years old, still ²more preferably an ²adult of at least 50 years old, even more preferably an adult of at least 60 ²years old.²The invention also relates to the use of a conjugate according to the ²invention, a prodrug²according to the invention or a pharmaceutical composition according to the ²invention, for the²preparation of a medicament. Preferably, it relates to a conjugate according ²to the invention, a ²prodrug according to the invention or a pharmaceutical composition according ²to the invention, ²for the preparation of a medicament for treating cancer and / or an inflammatory ²disease in a ²subject.²It further relates to a method for treating in a subject a cancer and / or an ²inflammatory disease, ²wherein a therapeutically effective amount of a conjugate according to the ²invention, a ²therapeutically effective amount of a prodrug according to the invention or a ²therapeutically ²effective amount of a pharmaceutical composition according to the invention, ²is administered² .. to said subject suffering from a cancer and / or an inflammatory disease.²It also relates to a method for treating in a subject a cancer and / or an ²inflammatory disease, ²wherein a therapeutically effective amount of a conjugate according to the ²invention, a ²therapeutically effective amount of a prodrug according to the invention or a ²therapeutically²effective amount of a pharmaceutical composition according to the invention, ²is administered²to said subject suffering from a cancer and / or an inflammatory disease, in ²combination with ²another treatment chosen from a group consisting of chemotherapy, ²radiotherapy, treatment ²with at least one anti-inflammatory agent, and combinations thereof²<DP=19>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²19²The conjugate according to the invention, the prodrug according to the ²invention or the ²pharmaceutical composition according to the invention may be administered by ²any convenient ²route to a subject in need thereof. For instance, it can be administered by a ²systemic route, in ²particular by subcutaneous, intramuscular, intravenous or intradermal, ²preferably by²intravenous, injection. The conjugate according to the invention, the prodrug ²according to the²invention or the pharmaceutical composition according to the invention may be ²administered ²as a single dose or in multiple doses. The conjugate according to the ²invention, the prodrug ²according to the invention or the pharmaceutical composition according to the ²invention may ²be administered between every day and every month, preferably every week or ²every two²weeks, more preferably every week. The duration of treatment with a conjugate ²according to²the invention, a prodrug according to the invention or a pharmaceutical ²composition according ²to the invention, is preferably comprised between 1 and 20 weeks, preferably ²between 1 and 10 ²weeks. Alternatively, the treatment may last as long as the symptoms of the ²disease persists. ²The amount of conjugate according to the invention, prodrug according to the ²invention or²pharmaceutical composition according to the invention to be administered has ²to be determined²by standard procedure well known by those of ordinary skills in the art. ²Physiological data of ²the patient (e.g. age, size, and weight) and the routes of administration have ²to be taken into ²account to determine the appropriate dosage, so as a therapeutically effective ²amount will be ²administered to the patient.² Cancer ²The term "cancer" or "tumor", as used herein, refers to the presence of cells ²possessing ²characteristics typical of cancer-causing cells, such as uncontrolled ²proliferation, and / or ²immortality, and / or metastatic potential, and / or rapid growth and / or ²proliferation rate, and / or²certain characteristic morphological features. This term refers to any type of ²malignancy²(primary or metastases) in any type of subject. It may refer to solid tumor as ²well as ²hematopoietic tumor.²Preferably, the cancer according to the invention is selected from the group ²consisting of the ²prostate cancer, the lung cancer, the breast cancer, the gastric cancer, the ²kidney cancer, the²ovarian cancer, the hepatocellular cancer, the osteosarcoma, the melanoma, the ²hypopharynx²cancer, the esophageal cancer, the endometrial cancer, the cervical cancer, ²the pancreatic ²cancer, the liver cancer, the colon or colorectal cancer, the neuroendocrine ²tumors, the ²malignant tumor of the muscle, the adrenal cancer, the thyroid cancer, the ²uterine cancer, the ²skin cancer, the bladder cancer, the head and neck cancer, the lymphoma, and ²the leukemia.²<DP=20>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²The conjugates of this invention, prodrugs of this invention or pharmaceutical ²compositions of ²this invention particularly aim at treating breast, colon, ovarian, prostate, ²pancreatic and lung ²cancers.²5²The conjugates of this invention, prodrugs of this invention or pharmaceutical ²compositions ²may be employed, for use thereof in the prevention and / or treatment of ²metastases.²Inflammatory diseases ²10 The term "inflammatory disease", as used herein, refers in particular to ²chronic pathological ²conditions of the intestine or rheumatoid pathological conditions.²EXAMPLES²15 This invention will be better understood in light of the following ²examples, which are provided ²for illustrative purposes only.²Method 1 ¨ preparative HPLC²The preparative HPLC system consisted of two Shimadzu LC-8A pumps, an SPD-10A ²VP²20 detector (Shimadzu), an SCL-10A VP controller (Shimadzu), an SIL-10A ²autosampler, a 2 mL ²sample loop and a SunFire C18 column (150 mm x 19 mm i.d., 5 gm, Waters). The ²sample was ²injected into the sample loop and eluted at 17 ml / min flow rate (50 min run, ²detection at 254 ²nm; buffer A: H20 miliQ + 0.05% of TFA; buffer B: acetonitrile; gradient: 40 ²min ¨ from 5% ²to 95% B, 5 min ¨ 95% B, 5 min ¨ 5% B).² Method 2 ¨ analytical HPLC²The analytical HPLC was run on Waters 2695 separation modules equipped with ²Waters 2487 ²UV detector and Gemini-NX, 5gm, C18, 150 x 4.6 mm column. The flow rate was 1 ²ml / min. ²Solvent A: 0.05% TFA in water. Solvent B: 0.05% TFA in acetonitrile. Gradient ²run: 0-1 min²- 30% B; 1-11 min ¨ 30% to 80%B; 11-12 min ¨ 80 to 95%B; 12-14.5 min ¨ 95% B; ²14.5-²14.7 min ¨ 95% to 30% B; 14.7-17 min ¨ 30% B.²<DP=21>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²21²Method 3 ¨ LCMS²The LCMS was run on Waters 2695 separation modules equipped with Waters 2487 ²UV ²detector, Waters Acquity QDa mass detector and CORTECS, 2.7 gm, C18, 50 x 4.6 ²mm ²column. The flow rate was 1 ml / min. Solvent A: 0.05% HCOOH in water. Solvent ²B: 0.05%²HCOOH in acetonitrile. Gradient run: 0-5 min ¨ 5% to 95% B; 5-6 min ¨ 95% B; 6-²7.8 min ¨²5% B. Mass detector was operated in positive MS Scan mode with 600 C probe ²temperature, ²1.5 kV capillary voltage and 10 V cone voltage.²Method 4 ¨ chiral HPLC²Chiral HPLC was run on Shimadzu SCL-10AVP system equipped with Shimadzu SIL-²10A²Autosampler, Shimadzu SCL-10AVP UV Detector (set to 254 nm), two Shimadzu LC-²8A ²pumps, CHIRALPAKO IG Semi-Prep Column (5gm, ID 20mm x L 250mm) and a 2 mL ²sample loop. The flow rate was 20 ml / min. The eluent was dichloromethane. The ²separation ²was run for 5 minutes.² Method 5 ¨ chiral HPLC²Chiral HPLC was run on Shimadzu SCL-10AVP system equipped with Shimadzu SIL-²10A ²Autosampler, Shimadzu SCL-10AVP UV Detector (set to 254 nm), two Shimadzu LC-²8A ²pumps, CHIRALPAKO IG Semi-Prep Column (5gm, ID 20mm x L 250mm) and a 2 mL²sample loop. The flow rate was 20 ml / min. The eluent was a mixture of heptane ²and ethanol²(70:30). The separation was run for 25 minutes.²Synthesis of the racemic mixture of compounds R1 and Si² HO .so HO²0 NO2 NO2² OH OH² R1 S1²(R)-4-(1-hydroxybut-3-yn-1-yI)-2-nitrophenol (S)-4-(1-hydroxybut-3-yn-1-yI)-²2-nitrophenol²To a flask equipped with a refrigerant and an addition funnel, aluminum powder ²(6.17 eq., ²14156 mg, 524 mmol) and a catalytic quantity of HgC12 (0.00248 eq., 57.2 mg, ²0.211 mmol) ²were covered with anhydrous THF (218 mL). Propargyl bromide (6.2 eq., 78439 ²mg, 58.8 mL, ²527 mmol) 80% solution in toluene was then added dropwise (attention: an ²exothermic reaction;²<DP=22>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²22²the peak of the exotherm and its intensity depend on the dispersity of ²aluminum powder). When ²the addition was over, the resulting reaction mixture was refluxed for 6 ²hours. The solution was ²then cooled to 0 C and a solution of 4-hydroxy-3-nitrobenzaldehyde (1 eq., ²14210 mg, 85 ²mmol) in THF (109 mL) was added dropwise. After 30 min of stirring, the ²aldehyde²disappeared completely (controlled by TLC) and the reaction was cooled down to ²0 C. The²reaction mixture was quenched by a dropwise addition of 1 N HC1 (10 mL), and ²then extracted ²3 times with Et0Ac. The organic layer was dried over MgSO4, and then ²evaporated to yield ²brown oil, which was purified by flash chromatography (cyclohexane / Et0Ac - ²70 / 30). In order ²to eliminate traces of Wurtz reaction byproduct, the resulting yellow oil was ²solubilized in²DCM (655 mL), the organic layer was extracted 3 times with 1 N NaOH solution ²(1 / 3 of DCM²volume each time). To the obtained combined aqueous layer was then added DCM ²(equal ²volume). The reaction mixture was acidified with concentrated HC1 until pH 1. ²The aqueous ²phase was extracted 3 more times with DCM (1 / 3 of the aqueous solution volume ²each). The ²combined organic layer was dried over MgSO4 and evaporated to yield the ²racemic mixture of²(R)-4-(1-hydroxybut-3-yn-1-y1)-2-nitrophenol and (S)-4-(1-hydroxybut-3-yn-1-²y1)-2-²nitrophenol mixture (7927 mg, 38.3 mmol, 45 %).²1H NMR (CHLOROFORM-d) Shift: 10.63 (s, 1H), 8.23 (s, 1H), 7.73 (dd, J = 8.5, ²1.5 Hz, ²1H), 7.25 (d, J = 8.5 Hz, 1H), 4.97 (t, J = 6.1 Hz, 1H), 2.67 - 2.97 (m, 3H), ²2.20 (t, J = 2.5 Hz, ²1H).²13C NMR (CHLOROFORM-d) Shift: 154.6, 135.2, 135.0, 133.3, 122.3, 120.1, 79.6, ²71.9,²70.8, 29.3.²MS (ES!, Method 3) m / z: 230.1 [M+Na]+²Separation of enantiomers RI and Si²Enantiomers RI and Si were separated using chiral chromatography. Chiral ²chromatography²was performed on the Shimadzu SCL-10AVP system equipped with Shimadzu SIL-10A ²Autosampler, Shimadzu SCL-10AVP UV Detector (set to 254 nm), Shimadzu FRC-10A ²Fraction Collector, two Shimadzu LC-8A pumps, CHIRALPAKO IG Semi-Prep Column ²(5 m, ID 20mm x L 250mm) and a 2 mL sample loop. Purification was performed at ²20 ml / min²flow rate using mixture of heptane and ethanol (70:30) as eluent. To 250 mg of ²the mixture of²R1 and Si were added 0.15 mL of ethanol and 0.35 mL of heptane. The resulting ²mixture was ²injected into the sample loop and the purification was run for 25 minutes. A ²first fraction ²containing pure R1 isomer was collected between 4 min and 8 min. A second ²fraction ²containing pure Si isomer was collected between 10 min and 22 min. Eluent was ²evaporated²<DP=23>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²23²and pure enantiomers R1 and Si were used in the following steps. Enantiomeric ²purity of R1²and Si was confirmed by chiral HPLC (Method 5).²Compound R1 HPLC (Method 5) RT: 6.53 min²Compound Si HPLC (Method 5) RT: 16.79 min² Compound R2²HO²HO .so²0²lei 0²0 0 NO2²=²NO2 (D9²OH²AcOµµ.y-,0Ac²R1 OAc²R2²A solution of HMTTA (0.7 eq., 2.11 g, 2.5 mL, 9.17 mmol; 1,1,4,7,10,10-²Hexamethyltriethylenetetramine, CAS 3083-10-1) and Ag2CO3 (3.7 eq., 13.4 g, ²48.5 mmol) in²anhydrous acetonitrile (20 mL) was stirred during 2 h at room temperature. (R)-²4-(1-²hydroxybut-3-yn-l-y1)-2-nitrophenol (1 eq., 2.71 g, 13.1 mmol) and ²(2R,3R,4S,5S,6S)-2-²bromo-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triy1 triacetate (1.1 eq., ²5.7 g, 14.3 ²mmol) solution in acetonitrile (11.9 mL) was added at 0 C, and the resulting ²mixture was stirred ²for 4 h at room temperature. The reaction was quenched with water, followed by ²the addition²of Et0Ac (50 mL). The obtained reaction mixture was stirred for 3 minutes, and ²then filtered ²to eliminate salts of silver. Extraction with 4 more portions of Et20 was ²conducted; the united ²organic fractions were dried over MgSO4 and evaporated. The resulting crude ²material was ²purified by flash chromatography (cyclohexane / Et0Ac gradient 0-100% of Et0Ac ²in 20 ²minutes; 30 column volumes) to yield methyl R2 (3428 mg, 6.55 mmol, 50 %) as a ²pale yellow² solid.²1H NMR (CHLOROFORM-d) Shift: 7.86 (dd, J = 6.1, 1.9 Hz, 1H), 7.49 - 7.65 (m, ²1H), 7.36²(d, J = 8.5 Hz, 1H), 5.25 - 5.39 (m, 3H), 5.17 - 5.25 (m, 1H), 4.90 (t, J = ²6.1 Hz, 1H), 4.21 (d,²J = 8.8 Hz, 1H), 3.74 (s, 3H), 2.53 - 2.70 (m, 2H), 1.98 - 2.20 (m, 10H).²13C NMR (CHLOROFORM-d) Shift: 170.0, 169.3, 169.3, 166.7, 148.5, 141.2, 138.9, ²131.2,²122.6, 120.0, 99.8, 90.3, 79.4, 72.6, 72.0, 71.2, 70.7, 70.2, 68.8, 53.0, ²29.4, 20.6, 20.5. ²MS (Method 3) m / z: 546.2 [M+Na]+²<DP=24>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²24²Compound S2²HO²HO²1.1²0 NO2² ________________________________________ i.-²NO2 0 0 0²)14²OH²AcO's.Y."OAc²S1²OAc²S2²A solution of HMTTA (0.7 eq., 3.4 g, 4 mL, 14.76 mmol; 1,1,4,7,10,10-²Hexamethyltriethylenetetramine, CAS 3083-10-1) and Ag2CO3 (3.7 eq., 21.5 g, 78 ²mmol) in²anhydrous acetonitrile (30 mL) was stirred during 2 h at room temperature. (S)-²4-(1-²hydroxybut-3-yn-1-y1)-2-nitrophenol (1 eq., 4.37 g, 21.1 mmol) and methyl ²(2R,3R,4S,5S,6S)-²2-bromo-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triy1 triacetate (1.1 ²eq., 10 g, 25.3 ²mmol) solution in acetonitrile (20 mL) was added at 0 C, and the resulting ²mixture was stirred²for 4 h at room temperature. The reaction was quenched with water, followed by ²the addition²of Et0Ac (80 mL). The obtained reaction mixture was stirred for 3 minutes, and ²then filtered ²to eliminate salts of silver. Extraction with 4 more portions of Et20 was ²conducted; the united ²organic fractions were dried over MgSO4 and evaporated. The resulting crude ²material was ²purified by flash chromatography (cyclohexane / Et0Ac gradient 0-100% of Et0Ac ²in 20²minutes; 30 column volumes) to yield S2 (6100 mg, 11.6 mmol, 55 %) as a pale ²yellow solid.²1H NMR (CHLOROFORM-d) Shift: 7.86 (dd, J = 6.1, 1.9 Hz, 1H), 7.49 - 7.65 (m, ²1H), 7.36 ²(d, J = 8.5 Hz, 1H), 5.25 - 5.39 (m, 3H), 5.17 - 5.25 (m, 1H), 4.90 (t, J = ²6.1 Hz, 1H), 4.21 (d, ²J = 8.8 Hz, 1H), 3.74 (s, 3H), 2.53 - 2.70 (m, 2H), 1.98 - 2.20 (m, 10H).²13( NMR (CHLOROFORM-d) Shift: 170.0, 169.3, 169.3, 166.7, 148.5, 141.2, 138.9, ²131.2,²122.6, 120.0, 99.8, 90.3, 79.4, 72.6, 72.0, 71.2, 70.7, 70.2, 68.8, 53.0, ²29.4, 20.6, 20.5.²MS (Method 3) m / z: 546.3 [M+Na]+²<DP=25>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226² Compound R3² HO ,µ s OyO²0 0 Kin NO2 0²0 1 m .._, 2 0 1 m .._, ²0 0 0 0 0 0²AcOµµ.y.' / OAc AcOµµ.y.' / OAc²OAc OAc²R2 R3²To a solution of R2 (1 eq., 1600 mg, 3.05 mmol) and 4-nitrophenyl ²chloroformate (2 eq., 1230²5 mg, 6.1 mmol) in dry DCM (30 mL) was added pyridine (2.5 eq., 0.62 mL, ²7.62 mmol) at 0 C.²The mixture was stirred 1 hour at room temperature and then quenched with ²saturated aqueous ²NaHCO3. The mixture was extracted three times with DCM (same as reaction ²volume) and the ²combined organic layers were dried over MgSO4, filtered and concentrated in ²vacuo. ²Purification by flash chromatography (cyclohexane / Et0Ac gradient 0-100% of ²Et0Ac in 20²10 minutes; 30 column volumes) afforded R3 (1469 mg, 2.13 mmol, 70 %) as an ²off-white solid.²1H NMR (CHLOROFORM-d) Shift: 8.17 - 8.34 (m, 2H), 7.94 (d, J = 2.0 Hz, 1H), ²7.65 (dd, J ²= 8.7, 2.1 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.33 - 7.40 (m, 2H), 5.81 (t, J ²= 6.5 Hz, 2H), 5.21 ²- 5.43 (m, 4H), 4.25 (d, J = 8.8 Hz, 1H), 3.74 (s, 3H), 2.78 - 3.02 (m, 2H), ²2.13 (s, 3H), 2.09 - ²2.12 (m, 1H), 2.02 - 2.09 (m, 6H).²15 13( NMR (CHLOROFORM-d) Shift: 169.9, 169.2, 169.1, 166.7, 155.2, 151.5, ²149.5, 145.6,²141.2, 133.4, 132.1, 125.3, 123.6, 121.7, 119.9, 99.5, 72.7, 72.5, 71.0, 70.2, ²68.6, 53.0, 26.3,²20.6, 20.5, 20.5.²MS (Method 3) m / z: 711.2 [M+Na]+²HPLC (Method 4) RT: 2.77 min²<DP=26>²CA 03095146 2020-09-24² WO 2019 / 192979 PCT / EP2019 / 058226²26²Compound S3²HO 00²0{ 0 8 o2N²'W² 0 NO2 0 NO2²0 0 0²,,..0 0 (:) )L²AC(Y. y-,0Ac Acoo.y '''OAc²OAc OAc²S2 S3²To a solution of S2 (1 eq., 2600 mg, 5.0 mmol) and 4-nitrophenyl chloroformate ²(2 eq., 2000²mg, 9.9 mmol) in dry DCM (50 mL) was added pyridine (2.5 eq., 1 mL, 12.42 ²mmol) at 0 C.²The mixture was stirred 1 hour at room temperature, quenched with saturated ²aqueous NaHCO3. ²The mixture was extracted three times with DCM (same as reaction volume) and ²the combined ²organic layer was dried over MgSO4, filtered and concentrated in vacuo. ²Purification by flash ²chromatography in cyclohexane / ethyl acetate (cyclohexane / Et0Ac gradient 0-100% ²of Et0Ac²in 20 minutes; 30 column volumes) yielded S3 (2300 mg, 2.13 mmol, 68 %) as an ²off-white²solid.²1H NMR (CHLOROFORM-d) Shift: 8.17 - 8.34 (m, 2H), 7.94 (d, J = 2.0 Hz, 1H), ²7.65 (dd, J ²= 8.7, 2.1 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.33 - 7.40 (m, 2H), 5.81 (t, J ²= 6.5 Hz, 2H), 5.21 ²- 5.43 (m, 4H), 4.25 (d, J = 8.8 Hz, 1H), 3.74 (s, 3H), 2.78 - 3.02 (m, 2H), ²2.13 (s, 3H), 2.09 -² 2.12 (m, 1H), 2.02 - 2.09 (m, 6H).²13C NMR (CHLOROFORM-d) Shift: 170.0, 169.3, 169.2, 166.7, 155.2, 151.5, 149.5, ²145.6,²141.1, 133.4, 132.1, 125.4, 123.7, 121.7, 119.9, 99.5, 72.6, 72.5, 71.0, 70.2, ²68.6, 53.1, 26.2,²20.6, 20.6, 20.5.²MS (Method 3) m / z: 711.2 [M+Na]+² HPLC (Method 4) RT: 2.84 min²<DP=27>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²27²Compound R4²o o 1 o 1²is oyo sso²02N ²OH \)5#1y *s"²0 is H²1õõ / Y 0 0 lei ²0²0 NO2 N²(DAsC0 HO0 0 ²KinV.,.,-,2²d46 A,C²OAc R4 HO's ²OH²OH²R3²To the solution of R3 (1 eq., 41.3 mg, 0.06 mmol) and MMAE (1 eq., 43.1 mg, ²0.06 mmol) in²DMF (1.15 mL) was added a solution of HOBt (1 eq., 8.11 mg, 0.06 mmol) in ²pyridine (0.287 ²mL). The mixture was stirred at room temperature for 24h then diluted with ²Me0H (11.5 mL) ²and cooled to 0 C. To the resulting solution was added LiOH (10 eq., 1 M in ²H20, 0.6 mL, 0.6 ²mmol) and the mixture was incubated for at 4 C for 16h. The resulting solution ²was quenched²with HCOOH (20 eq., 1 M in H20, 1.2 mL, 1.2 mmol) and concentrated to 3 mL ²under reduced²pressure. The residue was purified by preparative HPLC (method 1) to yield R4 ²(41.9 mg,²0.0372 mmol, 62 %) as a pale yellow solid.²HPLC (Method 2) RT: 7.81 min²MS (Method 3) m / z: 1127.7 [M+H]+² Compound S4²0 0{0²8 r 0 0 11 0 1²02N ²w ²- H ='µC)²0 0²O²0²Ac00)LIC: 0 ² NO2²0²HO)0?0²µ. i0Ac '' ²OAc S4 ²HOI..Y.' / OH²S3 OH²To the solution of S3 (1 eq., 37.9 mg, 0.055 mmol) and MMAE (1 eq., 39.5 mg, ²0.055 mmol) ²in DMF (1.05 mL) was added a solution of HOBt (1 eq., 7.43 mg, 0.055 mmol) in ²pyridine²(0.263 mL). The mixture was stirred at room temperature for 24h then diluted ²with Me0H (10.5²mL) and cooled to 0 C. To the resulting solution was added LiOH (10 eq., 1 M ²in H20, 0.55 ²mL, 0.55 mmol) and the mixture was incubated for at 4 C for 16h. The resulting ²solution was ²quenched with HCOOH (20 eq., 1 M in H20, 1.1 mL, 1.1 mmol) and concentrated to ²3 mL²<DP=28>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²28²under reduced pressure. The residue was purified by preparative HPLC (method ²1) to yield S4²(36.6 mg, 0.0325 mmol, 59 %) as a pale yellow solid.²HPLC (Method 2) RT: 7.66 min²MS (Method 3) m / z: 1127.9 [M+H]+² Compound R5²0 0 0² / --,NNy 1\²,NoNy0 ²oc)()²OHr²\"" nr 0 40 N:=N²0 rOC)0²NO2²0 H²H000²0² R5 0 H²0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.2 eq.,²19 mg, 0.036 mmol) in dry DMF (0.5 mL) was added 2,5-dioxopyrrolidin-1-y1 6-²(2,5-dioxo-²2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.2 eq., 11.1 mg, 0.036 mmol) . The ²mixture was stirred ²at 21 C for 1 hour and then R4 (1 eq., 33.8 mg, 0.03 mmol) was added. A TBTA-²Cu(II) ²complex was prepared by mixing tris[(1-benzy1-1H-1,2,3-triazol-4-²y1)methyl]amine (0.2 eq., ²0.2 M in DMF, 0.03 mL, 0.006 mmol) and copper sulfate pentahydrate (0.2 eq., ²0.2 M in H20, ²0.03 mL, 0.006 mmol) and incubating at 21 C for 2 minutes. The TBTA-Cu(II) ²complex (0.2²eq., 0.1 M in DMF / H20 50 / 50, 0.06 mL, 0.006 mmol) was added to the reaction ²mixture ²followed by sodium ascorbate (1 eq., 1 M in H20, 0.03 mL, 0.03 mmol) . The ²resulting mixture ²was incubated at 21 C for 1 hour and purified by preparative HPLC to yield R5 ²(30.5 mg, ²0.0165 mmol, 55 %) as a white solid.²HPLC (Method 2) RT: 6.85 min² MS (Method 3) m / z: 924.2 [M+2I-1]2-72²<DP=29>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²29²Compound S5² 0 0 0²I²=õN 2..õ.N y0²OH²0 NI:=N²NH²0 NO2 0 \ \ 0²0²H000 H²0² S5 OH²0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.2 eq.,²15.8 mg, 0.03 mmol) in dry DMF (0.417 mL) was added 2,5-dioxopyrrolidin-1-y1 6-²(2,5-dioxo-²2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.2 eq., 9.25 mg, 0.03 mmol) . The ²mixture was stirred ²at 21 C for 1 hour and then S4 (1 eq., 28.2 mg, 0.025 mmol) was added. A TBTA-²Cu(II) ²complex was prepared by mixing tris[(1-benzy1-1H-1,2,3-triazol-4-²y1)methyl]amine (0.2 eq., ²0.2 M in DMF, 0.025 mL, 0.005 mmol) and copper sulfate pentahydrate (0.2 eq., ²0.2 M in H20,²0.025 mL, 0.005 mmol) and incubating at 21 C for 2 minutes. The TBTA-Cu(II) ²complex (0.2²eq., 0.1 M in DMF / H20 50 / 50, 0.05 mL, 0.005 mmol) was added to the reaction ²mixture ²followed by sodium ascorbate (1 eq., 1 M, 0.025 mL, 0.025 mmol) . The ²resulting mixture was ²incubated at 21 C for 1 hour and purified by preparative HPLC to yield S5 ²(26.8 mg, 0.0145 ²mmol, 58 %) as a white solid.² HPLC (Method 2) RT: 6.65 min²MS (Method 3) m / z: 924.1 [M+2I-1]2-72²Compound R6a² 0 0 0²0 N²0 N 02²0 0²10)L²ACOµ'.²R6a OAc²To the solution of R3 (1 eq., 41.5 mg, 0.06 mmol) and MMAF (1 eq., 47.5 mg, ²0.06 mmol) in²DMF (1.3 mL) was added a solution of HOBt (1 eq., 8.14 mg, 0.06 mmol) in ²pyridine (0.291²<DP=30>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²mL). The mixture was stirred at room temperature for 66h, quenched with HCOOH ²(3 eq., 6.8 ²L, 0.18 mmol) and purified by preparative HPLC (Method 1) to afford R6a (57 ²mg, 0.043 ²mmol, 71% yield) as a white solid.²HPLC (Method 2) RT: 6.0 min² 5 MS (Method 3) m / z: 669.5 [M+2H]2-72²Compound 56a²\ / ²0 0²0 N²0 NO2²0 o0..,00²ACOµs' y.',0Ac²S6a OAc²To the solution of S3 (1 eq., 41.5 mg, 0.06 mmol) and MMAF (1 eq., 47.5 mg, ²0.06 mmol) in²10 DMF (1.3 mL) was added a solution of HOBt (1 eq., 8.14 mg, 0.06 mmol) in ²pyridine (0.291²mL). The mixture was stirred at room temperature for 66h, quenched with HCOOH ²(3 eq., 6.8 ²L, 0.18 mmol) and purified by preparative HPLC (method 1) to afford 56a (26.6 ²mg, 0.02 ²mmol, 33% yield) as a white solid.²HPLC (Method 2) RT: 6.0 min² 15 .. MS (Method 3) m / z: 669.4 [M+2H]2-72²Compound R6b²0 0 1 0 1²(--NNI-rN).'y .=''²0 \õ,.²H ='µCI ..õ..--No l.. / 0 40²HO N²0 NO2²0²H0)L0..,õ,0²HOµs.y.''OH²R6 b OH²To the solution of R6a (1 eq. 26.5 mg, 0.02 mmol) in MeCN (233 L) was added ²concentrated²20 aqueous HC1 (233 L) and the solution was stirred at 40 C for 20h. The ²mixture was then²diluted with 0.5 mL of MeCN and centrifuged to separate the precipitate. The ²supernatant was²<DP=31>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²31²purified by preparative HPLC (method 1) to afford R6b (6.7 mg, 5.9 iumol, 30% ²yield) as an²off-white solid.²HPLC (Method 2) RT: 4.4 min²MS (Method 3) m / z: 1141.6 [M+H]+² Compound 56b²0 0 1 0 1²0²Ni`il-Ny ² H CHAõ , . 0² HO N²0 N 02²0²HO...-ILõ.-0,,õ.0²HOµs.y.' / OH² S6b OH²To the solution of 56a (1 eq. 26.5 mg, 0.02 mmol) in MeCN (233 L) was added ²concentrated ²aqueous HC1 (233 L) and the solution was stirred at 40 C for 20h. The mixture ²was then²diluted with 0.5 mL of MeCN and centrifuged to separate the precipitate. The ²supernatant was²purified by preparative HPLC (method 1) to afford 56b (10.4 mg, 9.1 iumol, 46% ²yield) as an²off-white solid.²HPLC (Method 2) RT: 4.4 min²MS (Method 3) m / z: 1141.6 [M+H]+² Compound R6²\ / ²0 0 1 , 0 I² N / 11\,....õ.".L. N ,..r.;' ===== N (R)²N...---.,...õ..0...,....õ..---.,0,-----.,..õ..0,1² 0 \ JL)o H²H '' rOC)0)²HO N nw 0 0 0 N:=N² 0 NO2 0 .,......... / ',... 0 / 0 ..õ...........-",,o²0²HO).L,O0 01\1 1²H ²0²HOµs.Y.' / OH ._.... / C / \ / ²R6 OH \²0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.2 eq.,²3.53 mg, 6.7 iumol) in dry DMF (0.15 mL) was added a solution of 2,5-²dioxopyrrolidin-1 -yl 6-²(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.2 eq., 2.07 mg, 6.7 iumol) ²in dry DMF²<DP=32>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²32²(0.15 mL). The mixture was stirred at 21 C for 1 hour and then R6b (1 eq., 6.4 ²mg, 5.6 gmol) ²in DMSO (0.15 mL) was added. A THPTA-Cu(II) complex was prepared by mixing ²tris(3-²hydroxypropyltriazolylmethyl)amine (1.5 eq., 0.1 M in DMF, 0.084 mL, 8.4 gmol) ²and copper ²sulfate pentahydrate (1.5 eq., 0.1 M in H20, 0.084 mL, 8.4 gmol) and ²incubating at 21 C for 1²minute. The THPTA-Cu(II) complex (1.5 eq., 0.05 M in DMF / H20 50 / 50, 0.168 mL, ²8.4 gmol)²was added to the reaction mixture followed by sodium ascorbate (7.46 eq., 0.5 ²M in H20, 0.084 ²mL, 41.5 gmol). The resulting mixture was incubated at 21 C for 15 min and ²purified by ²preparative HPLC (method 1) to yield R6 (3.7 mg, 1.99 gmol, 36 %) as a white ²solid.²HPLC (Method 2) RT: 4.18 min² MS (Method 3) m / z: 931.1 [M+2H]2+ / 2²Compound S6²\ / ² 0 0 1 0 1² N N)=\1y0(s)²--- 0o0 ²rOC)0)²HO N²0 NO2 0 0 ²o²ff 0²HO)L'0 .0.0 H 1²0 N²0²HOµs.Y.' / OH _._.f.\ / .\ / ²S6 OH \²0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.2 eq.,²4.63 mg, 8.8 gmol) in dry DMF (0.15 mL) was added a solution of 2,5-²dioxopyrrolidin-1 -yl 6-²(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.2 eq., 2.71 mg, 8.8 gmol) ²in dry DMF ²(0.15 mL). The mixture was stirred at 21 C for 1 hour and then 56b (1 eq., 8.3 ²mg, 7.3 gmol) ²in DMSO (0.15 mL) was added. A THPTA-Cu(II) complex was prepared by mixing ²tris(3-²hydroxypropyltriazolylmethyl)amine (1.5 eq., 0.1 M in DMF, 0.109 mL, 10.9 ²gmol) and copper²sulfate pentahydrate (1.5 eq., 0.1 M in H20, 0.109 mL, 10.9 gmol) and ²incubating at 21 C for²1 minute. The THPTA-Cu(II) complex (1.5 eq., 0.05 M in DMF / H20 50 / 50, 0.218 ²mL, 10.9 ²gmol) was added to the reaction mixture followed by sodium ascorbate (7.46 ²eq., 0.5 M in H20, ²0.109 mL, 54.4 gmol). The resulting mixture was incubated at 21 C for 15 min ²and purified by ²preparative HPLC (method 1) to yield S6 (6.2 mg, 3.33 gmol, 46 %) as a white ²solid.² HPLC (Method 2) RT: 4.14 min²MS (Method 3) m / z: 931.1 [M+2H]2+ / 2²<DP=33>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²33²Compound 7a² OH 0 N3²0²N²I²+²OH / s N3²I²0 \ N Br²OH / ²0 0 0 \ N²7a²SN-38 0 0²To a solution of SN-38 (1 eq., 72.2 mg, 0.18 mmol) and 1-azido-4-²(bromomethyl)benzene (1²eq., 39 mg, 0.18 mmol) in DMF (7.22 mL) was added K2CO3 (3 eq., 76.3 mg, 0.55 ²mmol). The²resulting solution was purged with nitrogen, and stirred for lh at room ²temperature to allow the²formation of 7a. Crude 7a (92 mg, 0.18 mmol, 96%) was used in the next step ²without further ²purification.²MS (Method 3) m / z: 524.2 [M+FI]'² Compound 7b²0 NH2²0²N²1²OH / ² 0 \ N²7b²0 0²To a solution of 7a (1 eq., 96 mg, 0.18 mmol) in DMF (3mL) was added tris(2-²carboxyethyl)phosphine hydrochloride (TCEP, 1.3 eq., 68.33 mg, 0.24 mmol), ²followed by the ²addition of K2CO3 (3 eq., 76 mg, 0.55 mmol). The mixture was stirred for 1 ²hour, then 5x²volume of Et0Ac was added, followed by lx volume of water. Organic layer was ²separated,²and aqueous layer was extracted with another 5x volume of Et0Ac. Combined ²organic layer ²was dried over MgSO4 and concentrated under vacuum to yield 7b (90 mg, 0.18 ²mmol, 99%) ²as a pale yellow solid. Crude 7b was used in the next step without further ²purification.²MS (Method 3) m / z: 498.2 [M+FI]'²<DP=34>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²34²Compound R7c²H²N,,.0 0²II 's²0 40 0 0²N OAc NO2²I²OH / AcOro0²0 \ N²R7c²AcO's.I ²0² 0 0 0²A solution of R3 (1 eq., 82 mg, 0.12 mmol), 7b (1 eq., 59 mg, 0.12 mmol) and ²HOBt (1 eq., 16²mg, 0.12 mmol) in DMF (2.4 mL) was stirred at 25 C for 16 hours. The resulting ²mixture was²purified by preparative HPLC (method 1) to yield R7c (45 mg, 0.043 mmol, 36%) ²as a pale²yellow solid.²MS (Method 3) m / z: 1047.3 [M+H]+²Compound 57c²H²N ,,.0²H²0 1.1 0,²N OAC NO2²I²0 H AcOro0²0 \ N²AcO's²0²0 S7c 0 0²A solution of S3 (1 eq., 82 mg, 0.12 mmol), 7b (1 eq., 59 mg, 0.12 mmol) and ²HOBt (1 eq., 16 ²mg, 0.12 mmol) in DMF (2.4 mL) was stirred at 25 C for 16 hours. The resulting ²mixture was ²purified by preparative HPLC (method 1) to yield 57c (63 mg, 0.06 mmol, 50%) ²as a pale ²yellow solid.² MS (Method 3) m / z: 1047.3 [M+H]+²<DP=35>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226² Compound R7d²N o²'s²0 1.1 0² N OH NO2²OH H04.1rA0²0 N HOµs. CC)²0 0 R7d HOO²To a solution of R7c (1 eq., 23 mg, 22 iumol) in Me0H (20 mL) was added 1M ²aqueous solution ²of LiOH (200 eq., 4.4 mL, 4.4 mmol). The resulting reaction mixture was ²stirred at 25 C for 4h²5 and purified by preparative HPLC to yield R7d (16 mg, 0.018 mmol, 80%) as ²a pale yellow²solid.²MS (Method 3) m / z: 907.3 [M+H]+²Compound 57d²N²0 1.1 0 10² N OH NO2²1²OH HOO²0 N HOµs.r ²0 0 S7d HOO²To a solution of 57c (1 eq., 23 mg, 22 iumol) in Me0H (20 mL) was added 1M ²aqueous solution ²of LiOH (200 eq., 4.4 mL, 4.4 mmol). The resulting reaction mixture was ²stirred at 25 C for 4h ²and purified by preparative HPLC to yield 57d (13.9 mg, 0.016 mmol, 69.6%) as ²a pale yellow ²solid.² MS (Method 3) m / z: 907.3 [M+H]+²<DP=36>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²36²Compound R7²t\-11²101 H (R)²0 0 N:94² 10²1 OH NO2 0()0()²OH 0²0²0 N²R7²HO . Y)²0²0 HOO 0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.5 eq.,²5.92 mg, 11.3 iumol) in dry DMF (0.1 mL) was added a solution of 2,5-²dioxopyrrolidin-1 -yl 6-²5 (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.5 eq., 3.47 mg, 11.3 ²iumol) in dry DMF²(0.1 mL). The mixture was stirred at 21 C for 1 hour and then R7d (1 eq., 6.8 ²mg, 7.5 iumol) in ²DMSO (0.1 mL) was added. A THPTA-Cu(II) complex was prepared by mixing tris(3-²hydroxypropyltriazolylmethyl)amine (0.5 eq., 0.1 M in DMF, 37.5 L, 3.75 ²iumol) and copper ²sulfate pentahydrate (0.5 eq., 0.1 M in H20, 37.5 L, 3.75 iumol) and ²incubating at 21 C for 1²10 minute. The THPTA-Cu(II) complex (0.5 eq., 0.05 M in DMF / H20 50 / 50, 75 ²L, 3.75 iumol)²was added to the reaction mixture followed by sodium ascorbate (2.5 eq., 0.5 M ²in H20, 37.5 ²L, 18.75 iumol). The resulting mixture was incubated at 21 C for 15 min and ²purified by ²preparative HPLC (method 1) to yield R7 (6.95 mg, 4.28 iumol, 57 %) as a white ²solid.²HPLC (Method 2) RT: 3.92 min² MS (Method 3) m / z: 813.9 [M+2I-1]2-72²Compound S7²0 1.1 N 0²v(S)²0²rOC)0² N OH NO2 ()0()()²1²OH 0²0²0 N²S7²HO . Y)²0²0 HOO 0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.5 eq.,²5.92 mg, 11.3 iumol) in dry DMF (0.1 mL) was added a solution of 2,5-²dioxopyrrolidin-1 -yl 6-²(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.5 eq., 3.47 mg, 11.3 iumol) ²in dry DMF²<DP=37>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²37²(0.1 mL). The mixture was stirred at 21 C for 1 hour and then S7d (1 eq., 6.8 ²mg, 7.5 gmol) in ²DMSO (0.1 mL) was added. A THPTA-Cu(II) complex was prepared by mixing tris(3-²hydroxypropyltriazolylmethyl)amine (0.5 eq., 0.1 M in DMF, 37.5 L, 3.75 gmol) ²and copper ²sulfate pentahydrate (0.5 eq., 0.1 M in H20, 37.5 L, 3.75 gmol) and ²incubating at 21 C for 1²minute. The THPTA-Cu(II) complex (0.5 eq., 0.05 M in DMF / H20 50 / 50, 75 L, ²3.75 gmol)²was added to the reaction mixture followed by sodium ascorbate (2.5 eq., 0.5 M ²in H20, 37.5 ²L, 18.75 gmol). The resulting mixture was incubated at 21 C for 15 min and ²purified by ²preparative HPLC (method 1) to yield S7 (7.44 mg, 4.58 gmol, 61 %) as a white ²solid.²HPLC (Method 2) RT: 3.95 min² MS (Method 3) m / z: 813.9 [M+2I-1]2-72²Compound R8a²s 0 0y0 .so 02N 0 0y0 ².,"²02N 40 0 0²0 NO2 0 NO2²0²HO)L.00²AcO`sc². '''OAc ²HOµµ.y.' / OH²OAc OH²R3 R8a²To a solution of R3 (1 eq., 317 mg, 0.46 mmol) in acetonitrile (2 mL) was ²added concentrated²HC1 (52.2 eq., 2 mL, 24 mmol) and the mixture was stirred at 37 C for 16h. To ²the resulting²mixture was added Et0Ac (8 mL), followed by the addition of water (8 mL). The ²organic layer ²was separated and the aqueous layer was extracted three times with Et0Ac. ²Combined organic ²layer was dried over MgSO4 and concentrated under vacuum to yield the crude ²R8a (250 mg, ²0.46 mmol, 99%), which was used in the next step without further purification.² MS (Method 3) m / z: 549.1 [M+H]+²<DP=38>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²38²Compound S8a²0y0 0y0²0 0²02N 02N²0 NO2 0 NO2²0 0²HO)L0 0²0)L²Acoo.y.',0Ac HO . y²OAc OH²S3 S8a².. To a solution of S3 (1 eq., 317 mg, 0.46 mmol) in acetonitrile (2 mL) was ²added concentrated²HC1 (52.2 eq., 2 mL, 24 mmol) and the mixture was stirred at 37 C for 16h. To ²the resulting ²mixture was added Et0Ac (8 mL), followed by the addition of water (8 mL). The ²organic layer ²was separated and the aqueous layer was extracted three times with Et0Ac. ²Combined organic ²layer was dried over MgSO4 and concentrated under vacuum to yield the crude ²S8a (247 mg,²0.45 mmol, 98%), which was used in the next step without further purification.²MS (Method 3) m / z: 549.1 [M+H]+²Compound R8b²0²0²0 OH²HO 0.,%1\1 y0²C).''01-1 ²OH²0 OH NO2²OH HOO²HOµs.)r ²R8b HOO²To a solution of doxorubicin hydrochloride (1 eq., 10 mg, 0.017 mmol) in DMF ²(0.35 mL) was²added a solution of TEA (2 eq., 0.35 mL, 0.1 M in DMF, 0.035 mmol), followed ²by the addition ²R8a (1 eq., 9.5 mg, 0.017 mmol). The resulting mixture was stirred at 25 C for ²16h and purified ²by preparative HPLC (method 1) to yield R8b (12.2 mg, 0.013 mmol, 74%) as a ²red solid.²<DP=39>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²39²MS (Method 3) m / z: 953.3 [M+H]+²Compound 58b²0²0²0 OH²HO 04õõ(.......,µ Ny0²C)."OH ²OH²0 01-1. NO2²²OH HO : 0²HOµs.)r ²S8b HOO²To a solution of doxorubicin hydrochloride (1 eq., 10 mg, 0.017 mmol) in DMF ²(0.35 mL) was²added a solution of TEA (2 eq., 0.35 mL, 0.1 M in DMF, 0.035 mmol), followed ²by the addition ²58a (1 eq., 9.5 mg, 0.017 mmol). The resulting mixture was stirred at 25 C for ²16h and purified ²by preparative HPLC (method 1) to yield 58b (13.2 mg, 0.014 mmol, 80%) as a ²red solid. ²MS (Method 3) m / z: 953.3 [M+H]+² Compound R8²0²0²0 OH²HO 0 FN 0²y(R) .ss² ()."OH l\P:Ni²OH²0 OH NO2 0c) / C)c)²OH HO : 0 0N²0²HO\s'Y²R8 HOO²0²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.5 eq., ²11.82 mg, 22.45 iumol) in dry DMF (0.2 mL) was added a solution of 2,5-²dioxopyrrolidin- 1 -yl²6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.5 eq., 6.92 mg, 22.45 ²iumol) in dry DMF²<DP=40>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²(0.2 mL). The mixture was stirred at 21 C for 1 hour and then R8b (1 eq., 12 ²mg, 14.97 gmol) ²in DMSO (0.2 mL) was added. A THPTA-Cu(II) complex was prepared by mixing ²tris(3-²hydroxypropyltriazolylmethyl)amine (1 eq., 0.1 M in DMF, 150 L, 14.97 gmol) ²and copper ²sulfate pentahydrate (1 eq., 0.1 M in H20, 150 L, 14.97 gmol) and incubating ²at 21 C for 1²5 minute. The THPTA-Cu(II) complex (1 eq., 0.05 M in DMF / H20 50 / 50, 300 L, ²14.97 gmol)²was added to the reaction mixture followed by sodium ascorbate (2 eq., 0.5 M ²in H20, 60 L, ²29.94 gmol). The resulting mixture was incubated at 21 C for 15 min and ²purified by ²preparative HPLC (method 1) to yield R8 (14.35 mg, 9.43 gmol, 63 %) as a red ²solid.²HPLC (Method 2) RT: 3.70 min² 10 MS (Method 3) m / z: 836.9 [M+2H]2+ / 2²Compound S8²0²0²0 OH²AI 0²HO Y(N 0O0 ²S) ²1\1=-N'²rOC)0)²OH =²0 OH NO2 ()()()()²OH HO 0²0²HO\s'y²S8 HOO 0²Chemical Formula. C76H101N7035²Exact Mass. 1671,63²To the solution of 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-²amine (1.5 eq.,²15 11.82 mg, 22.45 gmol) in dry DMF (0.2 mL) was added a solution of 2,5-²dioxopyrrolidin- 1-y1²6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.5 eq., 6.92 mg, 22.45 ²gmol) in dry DMF ²(0.2 mL). The mixture was stirred at 21 C for 1 hour and then 58b (1 eq., 12 ²mg, 14.97 gmol) ²in DMSO (0.2 mL) was added. A THPTA-Cu(II) complex was prepared by mixing ²tris(3-²hydroxypropyltriazolylmethyl)amine (1 eq., 0.1 M in DMF, 150 L, 14.97 gmol) ²and copper²20 sulfate pentahydrate (1 eq., 0.1 M in H20, 150 L, 14.97 gmol) and ²incubating at 21 C for 1²minute. The THPTA-Cu(II) complex (1 eq., 0.05 M in DMF / H20 50 / 50, 300 L, ²14.97 gmol) ²was added to the reaction mixture followed by sodium ascorbate (2 eq., 0.5 M ²in H20, 60 L,²<DP=41>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²41²29.94 gmol). The resulting mixture was incubated at 21 C for 15 min and ²purified by²preparative HPLC (method 1) to yield S8 (15.5 mg, 10.18 gmol, 68 %) as a red ²solid.²HPLC (Method 2) RT: 3.65 min²MS (Method 3) m / z: 836.9 [M+2H]2+ / 2²Determination of absolute configuration of RI through Rla, by X-Ray ²crystallography²1) Preparation of R1 a²_²¨²HO .so HO (R)'²(R)²= NO2²0²NO2²OH² R1 R1 a²NO2²To determine absolute configuration of R1, ester RI a was synthesized, ²crystallized and²analyzed by X-ray crystallography. To a cooled to 0 C solution of RI (1 eq., ²111 mg, 0.536 ²mmol) and triethylamine (2 eq., 108 mg, 0.149 mL, 1.07 mmol) in THF (3.61 mL) ²was added ²dropwise a solution of 4- nitrobenzoyl chloride (1.5 eq., 149 mg, 0.804 mmol) ²in THF (3.61 ²mL). The resulting solution was warmed to room temperature and left for 30 ²minutes. Ethyl ²acetate (22 mL) was added followed by the addition of 7 mL of water. The ²organic layer was²separated and washed with saturated NaCl solution. The organic layer was ²evaporated and the ²residue was purified by flash chromatography (cyclohexane / Et0Ac gradient 0-²100% of Et0Ac ²in 20 minutes; 30 column volumes) to afford Rla (60.5 mg, 0.17 mmol, 88% ²yield).²2) Determination of absolute configuration of Rla by X-Ray crystallography²Rla (60 mg) was dissolved in 3 mL of dichloromethane and diluted with 3 mL of ²heptane. The ²mixture was allowed to slowly evaporate over a period of 2 weeks, inducing the ²formation of ²Rla crystals. The crystals were placed in oil, and a colourless plate single ²crystal of dimensions ²0.50 x 0.40 x 0.18 mm was selected, mounted on a glass fiber and placed in a ²low-temperature ²N2 stream. X-Ray diffraction data collection was carried out on a Bruker APEX ²II DUO Kappa-²CCD diffractometer equipped with an Oxford Cryosystem liquid N2 device, using ²Cu-Ka ²radiation (k = 1.54178 A). The crystal-detector distance was 40mm. The cell ²parameters were ²determined (APEX3 software) from reflections taken from three sets of 20 ²frames, each at lOs ²exposure. The structure was solved using the program SHELXT-2014. The ²refinement and all ²further calculations were carried out using SHELXL-2014. The hydrogen atom of ²one OH²<DP=42>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²42²group was located from Fourier difference. The other H-atoms were included in ²calculated²positions and treated as riding atoms using SHELXL default parameters. The non-²H atoms were²refined anisotropically, using weighted full-matrix least-squares on F2. A ²semi-empirical²absorption correction was applied using SADABS in APEX3; transmission factors: ²TminiTmax =² 0.6111 / 0.7528.²Results of the X-ray crystallography are presented on Figure 1.²Measurement of the kinetics of 13-glucuronidase-induced release of MMAE²= Sample solution of R isomer was prepared by adding 10 iut of R5 (10 mM in ²DMSO)²to 990 IA of human plasma and incubating at 37 C for 20 min.²= Sample solution of S isomer was prepared by adding 10 IA of S5 (10 mM in ²DMSO) ²to 990 IA of human plasma and incubating at 37 C for 20 min.²= Quenching solution (Q) was prepared by adding 50 IA of 1 M aqueous HC1 to ²1.5 mL² of acetonitrile.²= 13-glucuronidase solution (Glu) was prepared by adding 20 IA of aqueous ²glycerol ²solution of13-glucuronidase from Escherichia coli (6.5 mg / mL) to 180 ILIL of ²H20.²= Reference solution (Ref) was prepared by adding 10 IA of MMAE (10 mM in ²DMSO) ²to 990 IA of human plasma and incubating at 37 C for 20 min.²To 1 mL of each isomer and reference solution was added 40.9 uL of Glu. The ²resulting²mixtures were incubated at 37 C. 45 IA aliquots of each solution were quenched ²with 155 IA ²of Q at the following time points: 1 min, 2 min, 3 min, 4 min, 5 min, 6 min ²and 7 min. Quenched ²aliquots were centrifuged at 15000 g for 5 min and the supernatant was ²analyzed by LCMS ²(Method 3) with Selected ion recording set to 719 Da (corresponding to [MMAE-²41]). The²amount of released MMAE at each time point was calculated as (sample peak ²area) / (reference²peak area) x 100% (Figure 2).²General procedure for the measurement of the kinetics of 13-glucuronidase-²induced ²release of a cytotoxic drug²= Sample solution of R isomers was prepared by adding 5 IA of compounds R6, ²R7 or²R8 (10 mM in DMSO) to 500 ILIL of a 50 / 50 mixture of human plasma and ²potassium²phosphate buffer (0.1M, pH 7.0) and incubating at 37 C for 20 min.²<DP=43>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²43²= Sample solution of S isomers was prepared by adding 5 IA of compounds S6, ²S7 or S8 ²(10 mM in DMSO) to 500 IA of a 50 / 50 mixture of human plasma and potassium ²phosphate buffer (0.1M, pH 7.0) and incubating at 37 C for 20 min.²= Quenching solution (Q) was prepared by adding 50 L of 1 M aqueous HC1 to ²1.5 mL² of acetonitrile.²= 13-glucuronidase solution (Glu) was prepared by adding 20 IA of aqueous ²glycerol ²solution of13-glucuronidase from Escherichia coli (6.5 mg / mL) to 180 ILIL of ²H20.²= Reference solution (Ref) was prepared by adding 5 ILIL of a corresponding ²free cytotoxic ²drug (10 mM in DMSO) to 500 ILIL of a 50 / 50 mixture of human plasma and ²potassium²phosphate buffer (0.1M, pH 7.0) and incubating at 37 C for 20 min.²To each sample and reference solution was added 10 uL of Glu. The resulting ²mixtures were ²incubated at 25 C. 45 ILIL aliquots of each solution were quenched with 155 ²ILIL of Q at the ²precise time points indicated on the graphs (Figures 3-5). Quenched aliquots ²were centrifuged ²at 15000 g for 5 min and the supernatant was analyzed by LCMS (Method 3) with ²Selected ion²recording set to [M+H]+ where M corresponds to molecular mass of the free ²cytotoxic agent.²The amount of released cytotoxic agent at each time point was calculated as ²(sample peak ²area) / (reference peak area) x 100%.²Results are illustrated in Figure 2 to 5:²Figure 2. The kinetics of13-glucuronidase-induced release of MMAE in plasma ²solutions of R5 ²and S5 demonstrates a significantly faster cleavage of plasma-bound R5, ²compared to S5 : after ²7 minutes of incubation, 24 % of MMAE were released from plasma-bound R5 and ²only 12 % ²from plasma-bound S5.²Figure 3. The kinetics of13-glucuronidase-induced release of MMAF in plasma ²solutions of R6 ²and S6 demonstrates a significantly faster cleavage of plasma-bound R6, ²compared to S6 : after ²40 minutes of incubation, 86 % of MMAF were released from plasma-bound R6 and ²only 57 ²% from plasma-bound S6.²Figure 4. The kinetics of13-glucuronidase-induced release of SN-38 in plasma ²solutions of R7 ²and S7 demonstrates a faster cleavage of plasma-bound R7, compared to S7 : ²after 40 minutes²<DP=44>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²44²of incubation, 24 % of SN-38 were released from plasma-bound R7 and only 18 % ²from ²plasma-bound S7.²Figure 5. The kinetics of f3-glucuronidase-induced release of Doxorubicin in ²plasma solutions²of R8 and S8 demonstrates a faster cleavage of plasma-bound R8, compared to S8 ²: after 40²minutes of incubation, 99 % of Doxorubicin were released from plasma-bound R8 ²and 80 % ²from plasma-bound S8.²Measurement of the stability of R5 and S5 in aqueous buffer at pH 7.4²= Sample solution R5-PBS was prepared by adding 20 IA of R5 (10 mM in DMSO) to²180 L of phosphate buffered saline (pH 7.4).²= Sample solution S5-PBS was prepared by adding 20 L of S5 (10 mM in DMSO) ²to ²180 L of phosphate buffered saline (pH 7.4).²= Samples were incubated at 25 C and analyzed by LCMS (Method 3) with ²Selected ion²recording set to 924 Da (corresponding to [R5+2H]2+ / 2 and [S5+2H]2+ / 2) and to ²933 Da²(the main impurity being formed corresponding to hydrolyzed products ²[R5+H20+2H]2+ / 2 and [S5+H20+2H]2+ / 2). Samples were injected at the following ²time ²points: 0 min, 99 min, 195 min, 291 min, 387 min, 543 min, 699 min, 855 min, ²980 min. ²Peak areas of the samples injected at 0 min were considered as reference peak ²areas.²= % Peak Area was calculated as (924 Da peak area) / ((924 Da peak area) + (933 ²Da peak²area)) x 100%.²Results are illustrated in Figure 6. For both samples, a slow hydrolysis of ²the compound (R5 or ²S5) was observed at pH 7.4: 30-40 % of the compound is hydrolyzed after 1000 ²min.²The same experiment was carried out in phosphate buffered saline at pH 6.0. No ²degradation²of R5 or S5 was observed in these conditions at any time point.²Plasma-binding kinetics of R5 and S5²= Quenching solution (Q) was prepared by adding 50 IA of 1 M aqueous HC1 to ²1.5 mL² of acetonitrile.²= Sample solution R-Alb was prepared by adding 10 IA of R5 (10 mM in DMSO) ²to 990 ² L of human plasma and incubating at 37 C.²<DP=45>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²= Sample solution S-Alb was prepared by adding 10 IA of S5 (10 mM in DMSO) ²to 990 ²iut of human plasma and incubating at 37 C.²= 45 IA aliquots of each sample solution were added to 155 iut of the ²quenching solution ²at the following time-points: 0 min, 1 min, 2 min, 3 min, 4 min, 5 min, 6 min, ²7 min.²5 = Quenched aliquots were centrifuged at 15000 g for 5 min and the ²supernatant was²analyzed by LCMS (Method 3) with Selected ion recording set to 924 Da ²(corresponding to [R5+2H]2+ / 2 and [S5+2H]2+ / 2). Peak areas of the aliquots ²quenched ²at 0 min were considered as reference peak areas.²= The % remaining free drug at each time point was calculated as (sample ²peak² 10 area) / (reference peak area) x 100%.²Both compounds R5 and S5 undergo rapid binding reaction with serum albumin, ²resulting in a ²steep decline of the concentration of their free form, as shown in Figure 7. ²After 2 minutes of ²incubation, about 90 % of S5 or R5 was bound to serum albumin, and a total ²conversion was²15 obtained after 4 minutes.²Plasma stability of albumin-bound R5 and S5²= Sample solution R5-Alb was prepared by adding 10 IA of R5 (10 mM in DMSO) ²to ²990 ILIL of human plasma.²20 = Sample solution S5-Alb was prepared by adding 10 ILIL of S5 (10 mM in ²DMSO) to 990²ILIL of human plasma.²= Quenching solution (Q) was prepared by adding 50 IA of 1 M aqueous HC1 to ²1.5 mL ²of acetonitrile.²= Reference solution (Ref) was prepared by adding 10 IA of MMAE (10 mM in ²DMSO)² 25 to 990 IA of human plasma.²= Sample solutions and reference solution were incubated at 37 C²= 45 IA aliquots of each sample solution were added to 155 ILIL of the ²quenching solution ²at the following time-points: 0 h, 8 h, 24 h, 48 h, 102 h, 192 h.²= Quenched aliquots were centrifuged at 15000 g for 5 min and the ²supernatant was²30 analyzed by LCMS (Method 3) with Selected ion recording set to 719 Da²(corresponding to [MMAE-41]).²= % Released MMAE at each time point was calculated as (sample peak ²area) / (reference ²peak area) x 100%.²<DP=46>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²46²As shown in Figure 8, albumin-bound R5 and S5 remain stable in plasma, since ²only trace²amounts of the cytotoxic drug (MMAE) were released upon long-term incubation ²(less than²10% after 192 hours, i.e. 8 days, of incubation).² Separation tests²A test aiming at separating compounds R5 and S5 in a 1:1 mixture was carried ²out by HPLC ²according to Method 2 but has proven to be unsuccessful: as shown in Figure 9, ²very close RT's²of 6.72 and 6.83 minutes were obtained.²A similar test was carried out with a 1:1 mixture of R4 and S4, but separation ²has also proven²to be unsuccessful, since RT's of 7.56 and 7.72 minutes were obtained (Figure ²10).²
Claims
<DP=1>²CA 03095146 2020-09-24² WO 2019 / 192979 PCT / EP2019 / 058226²47²CLAIMS²1 . A conjugate represented by formula (I)²o²- H² 0 0² / H²0 N=N ²0²OH²* NO2²0²HOH ²0 H² (I),²wherein A represents a radical deriving from a cytotoxic drug,²G is a self-immolative moiety, and²m is 0 or 1,² and pharmaceutically acceptable salts thereof²2. A conjugate according to claim 1, wherein the cytotoxic drug is selected ²from anthracyclines, ²such as doxorubicin, dolastatins such as dolastatin 10, dolastatin 15, ²auristatin E, auristatin EB ²(AEB), auristatin EFP (AEFP), monomethyl auristatin F (MMAF), monomethyl ²auristatin D²(MMAD), monomethyl auristatin E (MMAE), 5-benzoylvaleric acid-AE ester (AEVB) ²or ²derivatives thereof, and camptothecin analogs such as SN-38.²3. A conjugate according to claim 2, wherein the cytotoxic drug is selected ²from the group²consisting of SN-38, doxorubicin, MMAF, MMAE, MMAD and derivatives thereof²4. A conjugate according to any one of claims 1 to 3, wherein G is represented ²by a formula ²selected from:²<DP=2>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²48²NrN)µ² H N 0²H N²H 0 ..-- -,,², and .²5. A prodrug comprising at least one molecule of the conjugate according to ²any one of claims ²1 to 4, said molecule of the conjugate being linked via a covalent bond to a ²protein molecule,² preferably albumin, or a fragment or a derivative thereof²6. The prodrug according to claim 5, wherein the covalent bond is established ²with the thiol ²function of the cysteine in position 34 of the albumin.²7. The prodrug according to claim 5, represented by formula (II),² / o o ²nPrt²- H²='µµµ NC)A<N)N² / H²0 H²0 I01 N=N 0²mn \ 0 H - -2²(II),²wherein A represents a radical deriving from a cytotoxic drug,²Prt represents a radical deriving from a protein,²n is comprised between 0.1 and 16, preferably between 0.1 and 8,²G is a self-immolative moiety, and²m is 0 or 1,² and pharmaceutically acceptable salts thereof²<DP=3>²CA 03095146 2020-09-24²WO 2019 / 192979 ²PCT / EP2019 / 058226²49²8. The prodrug according to claim 7, wherein Prt represents a radical deriving ²from albumin ²and n is 1.²9. A pharmaceutical composition comprising at least an effective amount of at ²least one²conjugate as defined according to any of claims 1 to 4 or at least one prodrug ²as defined²according to any of claims 5 to 8, and a pharmaceutically acceptable carrier.²10. The conjugate according to any of claims 1 to 4, for use in treating a ²cancer and / or an²inflammatory disease.²11. The prodrug according to any of claims 5 to 8, for use in treating a ²cancer and / or an ²inflammatory disease.²12. The pharmaceutical composition according to claim 9, for use in treating a ²cancer and / or an² inflammatory disease.²13. A process for preparing a conjugate as defined according to any of claims ²1 to 4, comprising ²the steps of:²a) preparing ² rac-4-(1-hydroxybut-3 -yn-1 -y1)-2 -nitro -phenol .. from .. 4-hydroxy-3 -²nitrobenzaldehyde;²b) separating and isolating (R)-4-(1-hydroxybut-3-yn- 1 -y1)-2-nitro-phenol, ²preferably by chiral ²high-performance liquid chromatography;²c) reacting (R)-4-(1-hydroxybut-3-yn- 1 -y1)-2-nitro-phenol with a glucuronic ²acid derivative, ²such as methyl acetobromo-a-D-glucuronate, under basic conditions;²d) reacting the compound obtained in step (c) with 4-nitrophenyl ²chloroformate;²e) coupling the compound obtained in step (d) with a cytotoxic drug or with an ²A-G-H moiety, ²in which A represents a radical deriving from a cytotoxic drug and G ²represents a self-²immolative moiety;²f) deprotecting the glucuronide moiety of the compound obtained in step (e), ²preferably under²basic conditions; and²g) coupling the compound obtained in step (f) with an azide of formula N3-(CH2-²CH2-0)io-²(CH2)2-NH-(C0)-(CH2)5-X, wherein X is a maleimide group.²
